Novartis Ag (NVS) Change in Receivables (2022 - 2024)
Novartis Ag (NVS) posted Change in Receivables of -$920.0 million for Q1 2024, down 8.24% sequentially from -$850.0 million in Q1 2023, and down 8.24% YoY from -$1.0 billion in Q2 2023.
Novartis Ag (NVS) Change in Receivables (2022 - 2024) Analysis & Trends
Novartis Ag (NVS) has 3 years of Change in Receivables data on file, last reported at -$920.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 595.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -87.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -413.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -134.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | -103.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -920.00 Mn |
| Mar 31, 2024 | -920.00 Mn |
| Mar 31, 2023 | -850.00 Mn |
| Mar 31, 2023 | -850.00 Mn |
| Mar 31, 2022 | -496.00 Mn |
| Mar 31, 2022 | -496.00 Mn |